Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)

Jie Cui, Chase W. Kessinger, Harkamal S. Jhajj, Madeleine S. Grau, Sanjay Misra, Peter Libby, Jason R. McCarthy, Farouc A. Jaffer

Research output: Contribution to journalComment/debatepeer-review

Abstract

Dr. Peter Libby inadvertently omitted the following statement from his disclosures: Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.

Original languageEnglish (US)
Pages (from-to)2230
Number of pages1
JournalJournal of the American Society of Nephrology
Volume31
Issue number9
DOIs
StatePublished - Sep 2020

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)'. Together they form a unique fingerprint.

Cite this